Cysteamine is a medication primarily used to treat cystinosis, a rare genetic disorder characterized by the accumulation of cystine within cells. Developed in the late 20th century, cysteamine became an essential therapy after it was shown to effectively reduce intracellular cystine levels and delay organ damage. It received regulatory approval in the 1990s and has since been incorporated into standard treatment protocols for cystinosis patients.
Its history highlights both its therapeutic benefits and the importance of long-term monitoring, as treatment requires lifelong adherence and careful dose management. Various formulations, including immediate-release and delayed-release versions, have been introduced to improve patient compliance and outcomes.
BRAND NAMES
Cystagon – immediate-release oral capsules
Procysbi – delayed-release oral capsules/granules.
MECHANISM OF ACTION
Cysteamine acts by reducing the accumulation of cystine within lysosomes, the primary defect in cystinosis. It enters lysosomes and reacts with cystine to form cysteine and a cysteine–cysteamine mixed disulfide. Unlike cystine, these products can exit the lysosome through alternative transport mechanisms, thereby bypassing the defective cystinosin transporter.
PHARMACOKINETICS
Absorption
Cysteamine is well absorbed after oral administration, particularly in its immediate-release form. Peak plasma concentrations are typically reached within about 1–2 hours. Food may delay absorption and reduce peak levels, which is why it is often recommended to take the medication on an empty stomach or as directed.
Distribution
Cysteamine has a moderate to wide volume of distribution, indicating that it distributes beyond the bloodstream into various tissues, including the kidneys, liver, and other organs affected in cystinosis. Its ability to enter cells and penetrate lysosomes is essential for its therapeutic action.
Metabolism
Cysteamine is extensively metabolized in the body, primarily in the liver. It undergoes oxidation to form hypotaurine and subsequently taurine, which are normal physiological compounds.
Elimination
Cysteamine and its metabolites are primarily eliminated via the kidneys. After hepatic metabolism to compounds such as taurine and other sulfur-containing products, these are excreted in the urine.
PHARMACODYNAMICS
Cysteamine exerts its pharmacodynamic effect by depleting intracellular cystine levels, thereby addressing the underlying defect in cystinosis. It acts within lysosomes to convert cystine into compounds that can be transported out of the cell, leading to a reduction in cystine crystal formation. This effect helps preserve cellular function and delays damage to organs such as the kidneys, eyes, and muscles.
ADMINISTRATION
Cysteamine is administered orally and ophthalmically depending on the clinical indication. The oral formulations are available as immediate-release capsules taken multiple times daily and delayed-release preparations that allow for less frequent dosing, typically twice daily. It is generally recommended to take the oral drug on an empty stomach to improve absorption and effectiveness, although administration with food may be used in patients with gastrointestinal intolerance.
DOSAGE AND STRENGTH
Cysteamine dosing is individualized based on body weight, clinical response, and leukocyte cystine levels. For oral therapy, immediate-release capsules are typically started at a low dose and gradually increased to a maintenance range, often around 1.3 to 1.95 g/m²/day, divided into doses given every 6 hours. Delayed-release formulations are usually administered at approximately the same total daily dose but split into twice-daily dosing, allowing improved adherence and more stable drug levels.
DRUG INTERACTIONS
Cysteamine has relatively few clinically significant drug–drug interactions, as it is not a major inducer or inhibitor of cytochrome P450 enzymes. However, its absorption and tolerability can be affected by other agents. Drugs that alter gastric conditions, such as antacids or proton pump inhibitors, may influence the absorption of oral cysteamine formulations.
FOOD INTERACTIONS
Cysteamine has important food interactions that mainly affect its absorption and tolerability. Food can significantly reduce or delay the absorption of oral cysteamine, leading to decreased peak plasma levels and reduced therapeutic effectiveness, particularly with immediate-release formulations.
CONTRAINDICATIONS
Cysteamine is contraindicated in patients with known hypersensitivity to cysteamine or any of its formulation components, as prior allergic reactions may be severe and potentially life-threatening. It should also be avoided in individuals who are unable to tolerate the drug due to significant gastrointestinal disease or severe adverse reactions that cannot be managed with dose adjustment.
SIDE EFFECTS
Nausea
Vomiting
Abdominal pain
Diarrhea
Loss of appetite (anorexia)
Headache
Dizziness
OVER DOSAGE
Overdosage of Cysteamine may lead to an exaggeration of its dose-related gastrointestinal and neurological adverse effects. Acute excessive intake commonly results in severe nausea, vomiting, abdominal pain, and diarrhea, which can progress to dehydration, hypotension, and electrolyte imbalance.
TOXICITY
Cysteamine toxicity is primarily related to dose-dependent exaggeration of its gastrointestinal and neurological adverse effects. Overdose or excessive plasma concentrations may lead to severe nausea, vomiting, abdominal pain, and diarrhea, which can progress to dehydration and electrolyte imbalance. Central nervous system toxicity may manifest as marked drowsiness, dizziness, lethargy, or, in severe cases, confusion.
